Polymyalgia Rheumatica: Difference between revisions

No edit summary
m (added a title on MDT Managment)
 
(111 intermediate revisions by 12 users not shown)
Line 1: Line 1:
 
<div class="editorbox">
<div class="noeditbox">Welcome to [[Pathophysiology of Complex Patient Problems|PT 635 Pathophysiology of Complex Patient Problems]] This is a wiki created by and for the students in the School of Physical Therapy at Bellarmine University in Louisville KY. Please do not edit unless you are involved in this project, but please come back in the near future to check out new information!!</div> <div class="editorbox">
'''Original Editors '''- Nicki Spencer [[Pathophysiology of Complex Patient Problems|from Bellarmine University's&nbsp;Pathophysiology of Complex Patient Problems project.]]  
'''Original Editors '''- Nicki Spencer [[Pathophysiology of Complex Patient Problems|from Bellarmine University's&nbsp;Pathophysiology of Complex Patient Problems project.]]  


'''Lead Editors''' - Your name will be added here if you are a lead editor on this page.&nbsp; [[Physiopedia:Editors|Read more.]]
'''Top Contributors''' - {{Special:Contributors/{{FULLPAGENAME}}}} <br>
</div>  
</div>
== Definition/Description  ==
== Definition/Description&nbsp; ==


&nbsp;&nbsp; &nbsp; Polymyalgia rheumatica (PMR) is a rheumatic inflammatory disorder that has no known cause. (DD book) It causes inflammation of the large muscles of the body and can be accompanied by constitutional symptoms, such as malaise, fatigue, fever, and weight loss. (PMR management guidelines) In patients with PMR, the synovial membranes and bursae that line and lubricate the joints become inflamed, causing pain and discomfort. Unlike in some other inflammatory diseases, there is no associated permanent damage to the joints or the muscles. (PMR management guidelines)
Polymyalgia rheumatica (PMR) is a rheumatic inflammatory disorder that has an unknown cause.<ref>Goodman, Snyder. Differential Diagnosis for Physical Therapists: Screening for Referral. St. Louis Missouri. 2007.</ref> It causes inflammation of the large muscles of the body and can be accompanied by systematic symptoms including malaise, fatigue, fever, and weight loss.<ref name=":0">LeGrove L. Polymyalgia rheumatica: management guidelines. Practice Nurse [serial online]. May 8, 2009;37(9):33-37. Available from: CINAHL with Full Text, Ipswich, MA. Accessed April 4, 2011.</ref> In patients with PMR, the synovial membranes and bursae that line and lubricate the joints become inflamed, causing pain and discomfort. Unlike in some other inflammatory diseases, there is no associated permanent damage to the joints or the muscles.<ref name=":0" /> Polymyalgia rheumatic is also known as muscular rheumatism.<ref name=":1">Reumafonds: polymyalgia rheumatica. http://www.reumalier.be/PDF-FILES/112.juli13_BS_Polymyalgia_Reumatica.pdf. Accessed July 2013. (LOE 5)</ref> PMR is a heterogeneous disease with a major impact on QOL. <ref>Hutchings A et al, Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica., Arthritis Rheum. 2007 Jun 15;57(5):803-9 LOE: 2a</ref><br>


== Prevalence ==
== Clinically Relevant Anatomy ==


&nbsp;&nbsp; &nbsp; In persons over the age of 50, PMR has a prevalence of approximately 700 per 100,00. (JRSM) Approximately 4 in 10,000 adults over the age of 60 develop PMR each year. (PMR management guidelines)
PMR is a condition that causes many (poly) painful muscles (myalgia)<ref>Arthritis New Zealand: http//www.arthritis.org.nz/wp-content/uploads/2012/06/4618_Polymyalgia_Flyer_4-1.pdf</ref>. PMR characteristically presents with pain and stiffness in the shoulder and hip girdles and an elevated acute phase response. <ref>Sara Muller et al., The epidemiology of polymyalgia rheumatica in primary care: a research protocol, BMC Musculoskelet Disord. 2012; 13: 102. LOE: 2a</ref>


== Characteristics/Clinical Presentation  ==
[[Image:Polymyalgiafoto1.GIF]]<br>


&nbsp;&nbsp; &nbsp; The onset of PMR is very sudden. Individuals can usually remember the exact time and day that they began experiencing symptoms. Individuals often wake up one morning with extreme stiffness and soreness for no apparent reason. (Path book)
== Epidemiology/etiology  ==
Although polymyalgia rheumatic occurs worldwide, the highest incidence is seen in Scandinavian countries and in people of the northern European descent. [16] In the United States the lifetime risk of developing PMR is estimated at 2.43% for women and 1.66% for men. The lowest incidence rates occur at the more southern European countries like Italy, and Spain. <ref>Advances and challenges in the diagnosis and treatment of polymyalgia rheumatica; Tanaz A. Kermani et al.; February 6 2014. LOE:2a</ref>


&nbsp;&nbsp; &nbsp; This disorder generally manifests itself in the muscles of the neck, shoulder girdle, and pelvic girdle. The pain and stiffness is often symmetric and bilateral. (Path book) Other signs and symptoms that can be seen include stiffness after rising in the morning or after resting, weakness, fatigue, malaise, low-grade fever, sweats, headache, weight loss, depression, and vision changes. (DD book)
PMR is most commonly diagnosed in persons over the age of 50, PMR has a prevalence of approximately 7 in 100 for people over 50 years of age and 4 in 10,000 in adults over 60 years of age. The prevalence is gender dependent with the ratio of men to women affected 1:2. <ref name=":1" /> The disease is more common in Caucasian.<br><ref name="Pitfalls in diagnosis">Siebert S, Lawson T, Wheeler M, Martin J, Williams B. Polymyalgia rheumatica: pitfalls in diagnosis. Journal Of The Royal Society Of Medicine [serial online]. May 2001;94(5):242-244. Available from: MEDLINE, Ipswich, MA. Accessed April 5, 2011.</ref>


&nbsp;&nbsp; &nbsp; Three primary risk factors that are associated with PMR are age, female gender, and race. This disease rarely occurs in individuals younger than 50 and most occur in individuals over the age of 70. Women are affected twice as much as men. PMR is more commonly seen in Caucasian women than women of any other ethnicity. (Path book)
<br>Some of the characteristics of PMR suggest that infectious disease expose could be an environmental factor. The disease has a very sudden onset and new cases occur in cycles, which could indicate an infection as the source. Attention has been focused on Chlamydia, Mycoplasma, parainfluenza virus or parvovirus B19 as possible infections responsible for developing PMR. Inheritance of the disorder has been suggested due to findings in some genetic studies and the pattern seen in family histories.<ref name=":2">Mayo Clinic: Polymyalgia rheumatica.http://www.mayoclinic.com/health/polymyalgia-rheumatica/DS00441. Accessed March 31, 2011.</ref> The gene(s) that could be responsible for PMR have not been definitively identified. The HLA-DRB104 and HLA-DRB01 alleles have both been found to have a possible link to PMR and GCA although this remains controversial.<ref name=":3">Nothnagl T, Leeb B. Diagnosis, Differential Diagnosis and Treatment of Polymyalgia Rheumatica. Drugs &amp;Aging [serial online]. May 2006;23(5):391. Available from: Academic Search Premier, Ipswich, MA. Accessed April 5, 2011.</ref>


== Associated Co-morbidities  ==
There may be an imbalance between immunosuppressive T-regulatory (Treg) lymphocytes and proinflammatory T-helper 17 (Th17) cells in PMR and giant cell arteritis (GCA). The frequency of Treg cells circulating appears to be reduced in patients with PMR compared with aged-matched volunteers. While on the other hand TH17 cells appear to be increased. <ref name=":2" /><br>


'''Giant Cell Arteritis'''<br>
&nbsp;&nbsp; &nbsp;  
&nbsp;&nbsp; &nbsp; Giant cell arteritis (GCA) is a condition that produces inflammation in the arteries. &nbsp;Approximately 1 in 20 people who are being treated for PMR, and about 7 in 20 with untreated PMR, develop GCA. (PMR management guidelines) &nbsp;The most common arteries affected are the temporal arteries. &nbsp;Temporal arteritis is an extremely serious condition and requires immediate medical attention. &nbsp;If left untreated, it could result in blindness.


&nbsp;&nbsp; &nbsp; Symptoms include (PMR management guidelines):
== Characteristics/Clinical Presentation  ==
 
[[File:Polymyalgiafoto2.GIF|center|frameless|677x677px]]
*headache or tenderness on one side of the head
&nbsp; &nbsp;
*&nbsp;scalp tenderness
*pain in the jaw when chewing, which eases quickly when the jaw is rested
*&nbsp;tongue or throat pain
*&nbsp;sudden loss of vision or any other sudden visual problem in one eye
*weakness
*numbness
*deafness
 
== Medications  ==


&nbsp;&nbsp; &nbsp; Corticosteroids If PMR is suspected to be the probable diagnosis for a patient, then a trial of low-dose corticosteroids is given. The response to corticosteroids is usually dramatic, and patients may report relief in symptoms after one dose. If symptoms are not better within 2-3 weeks of beginning the corticosteroid treatment, it is unlikely that the individual actually has PMR and more testing should be performed to find an appropriate diagnosis. (rheumatology.org)
The onset of PMR is very sudden. Individuals can usually remember the exact time and day that symptoms began. Individuals often wake up one morning with extreme stiffness and soreness for no apparent reason. Synovitis and bursitis of the shoulder and hip are the cause of the patient's pain and symptoms are typically bilateral<ref name=":3" /><br><br>Other symptoms that are found in 40-50% of patients and include:<br>• stiffness after rising in the morning lasting 30 min or longer or after resting<br>• weakness<br>• fatigue<br>• malaise<br>• low-grade fever<br>• sweats<br>• headache<br>• weight loss<br>• depression <br>• vision changes


&nbsp;&nbsp; &nbsp; If the patient has a favorable response to corticosteroids, they will continue to take a maintenance dosage for approximately 6 months to 2 years. (Path book) This maintenance dosage can help control the pain and stiffness associated with PMR. Over that time period, the dosage is gradually decreased until it is no longer needed. Complete clinical remission may take up to 5 years to occur. (Path book)
The symptom pattern is characteristic to PMR, although, several other autoimmune, infectious, endocrine and malignant disorders can present with similar symptoms. Ruling out the other illnesses is very important.  


== Diagnostic Tests/Lab Tests/Lab Values  ==
== Differential Diagnosis    ==


&nbsp;&nbsp; &nbsp; PMR is a diagnosis of exclusion. (JRSM) There are no definitive diagnostic tests to identify PMR. (Path book) Physicians will typically perform a physical exam, order blood tests, and perform imaging studies to determine if the patient’s symptoms are due to some other disorder. (Mayo clinic) Some clinicians use an erythrocyte sedimentation rate (ESR) of higher than 30 or 40 mm/hr as diagnostic criteria; however, there have been reports of individuals diagnosed with PMR having an ESR of normal or only slightly higher than normal so this may not be an appropriate criteria. (Path book)
There are many conditions that can mimic PMR, like rheumatoid arthritis (RA) and spondyloarthropathies (SpA). Pain and swelling of the distal joints, like feet, hands and wrists should raise concern for an inflammatory arthritis. Some patients may present swelling and pitting edema of the hands and the feet, because of a tenosynovitits. The so called remitting seronegative symmetrical synovitis with pitting edema syndrome.<ref name=":3" /><br>


== Etiology/Causes  ==
PMR must be differentiated from&nbsp;:


&nbsp;&nbsp; &nbsp; There is no clear cause for PMR; however, research has begun to suggest that it may occur due to a combination of environmental and genetic factors. (Mayo clinic)
'''Rheumatological diseases such as:'''


&nbsp;&nbsp; &nbsp; Certain characteristics of PMR suggest that an environmental cause could be an infectious disease. It has a very sudden onset and new cases occur in cycles, which could indicate an infection as the source. (Mayo clinic)
* [[Rheumatoid Arthritis]]
* [[Spondyloarthropathy--AS|Spondyloarthropathy]] 
* [[Crystalline Arthritis]] (calcium pyrophosphate disease and calcium hydroxyapatite disorders)
* Remitting seronegative symmetric synovitis with pitting oedema syndrome
* Connective tissue diseases
* Vasculitis (giant cell arteritis, antineutrophil cytoplasmic antibody-associated vasculitis).  
* Inflammatory myopathies (dermatomyositis, polymyositis )  


&nbsp;&nbsp; &nbsp; The gene(s) that could be responsible for PMR has not been identified. Inheritance of the disorder has been suggested due to findings in some genetic studies and a pattern seen in family histories. (Mayo clinic)
'''Non-inflammatory musculoskeletal disorders such as'''
* Rotator-cuff diseases (rotator cuff tears, rotator cuff tendinopathy)  
* [[Frozen Shoulder|Adhesive capsulitis]]
* Degenerative joint disease (degeneratieve disc disease)
* [[Fibromyalgia]] 
* Endocrinopathies
* Thyroid diseases
* Disorders of the parathyroid gland
* Infections - viral or bacterial i.e. sepsis, ends carditis, septic arthritis
* Mycobacterial – eg tuberculosis
* Malignant diseases
* Parkinsonism
* [[Depression]]
* Hypovitaminosis D
* Drug-induced myopathy-eg, from statins


== Systemic Involvement  ==
==Diagnostic Procedures==
Polymyalgia rheumatica is a clinical diagnosis . A careful history and physical examination are crucial in distinguishing this syndrome from other disorders that may present similarly, especially seronegative RA and paraneoplastic syndrome. Laboratory findings are non specific and show characteristic features of systemic inflammation. These include; anaemia, leukocytosis and raised markers of inflammation (ESR and CRP) and sometimes liver tests such as transaminases or alkaline phosphatase are raised. Some clinicians use an erythrocyte sedimentation rate (ESR) of higher than 30 or 40 mm/hr as a diagnostic criterium; however, 6-20% of patients with the disease have a normal sedimentation<ref name=":4">Tanza A Kermani et al, Polymyalgia rheumatic, Lancet 2013&nbsp;: 381&nbsp;: 63-72.LOE&nbsp;: 2A</ref>. Auto-antibodies including rheumatoid factor and antibody to cyclic citrullinated peptide, are usually negative, and if positive, RA must be considered.


add text here
Shoulder, hip, neck and upper arm pain associated with PMR is usually bilateral and symmetrical. Tenderness to palpation is expected however muscle weakness is not a feature of PMR. Usually, there will be minimal muscle atrophy unless the disease progression is advanced, when disuse atrophy can occur<ref>Clement J michet etal . Polymyalgia rheumatic . BMJ 2008;336. (LOE: 2A)</ref>. Active range of motion is generally reduced due to pain. The 24-hour picture pattern of PMR typically presents with severe morning stiffness that improves somewhat by the evening and following periods of rest. Pain may radiate and mild synovitis may be seen in the wrist and knees. Associated systemic symptoms may include fatigue, fever and weight loss.


== Medical Management (current best evidence) ==
Radiographs of the affected joints in PMR are only useful for excluding alternative conditions. In the classification study of the EULAR/ACR, they found a high specificity for ultrasonography for discriminating PMR from other shoulder conditions (89%), but not for discriminating PMR from RA (70%)<ref>Advances and challenges in the diagnosis and treatment of polymyalgia rheumatica; Tanaz A. Kermani et al.; February 6 2014. LOE:2a</ref>


add text here
Ultrasound (US) may be of value in the diagnosis of PMR. Shoulder abnormalities found using US, such as bursitis and tenosynovitis of the long head of the biceps tendon, is more likely to be seen in patients with PMR. However, in the absence of suggestive clinical features, the presence of isolated US abnormalities should not lead to a diagnosis of PMR.<ref>Sakellariou G et al, Ultrasound imaging for the rheumatologist XLIII. Ultrasonographic evaluation of shoulders and hips in patients with polymyalgia rheumatica: a systematic literature review. Clin. Exp. Rheumatol. 2013;31:1-7. LOE&nbsp;: 3A</ref>


== Physical Therapy Management (current best evidence)  ==
== Diagnostic Criteria ==
There are two sets of diagnostic criteria that have been created for PMR.


add text here
The Bird/Wood criteria<ref name=":5">Nothnagl T, Leeb B. Diagnosis, Differential Diagnosis and Treatment of Polymyalgia Rheumatica. Drugs &amp;Aging [serial online]. May 2006;23(5):391. Available from: Academic Search Premier, Ipswich, MA. Accessed April 5, 2011.</ref>, which includes:


== Alternative/Holistic Management (current best evidence) ==
<br>• Bilateral shoulder stiffness<br>• Duration onset &lt; 2 weeks<br>• Initial ESR &gt; 40 mm/hour<br>• Stiffness &gt; 60 minutes<br>• Age &gt; 65 years<br>• Depression and/or weight loss<br>• Bilateral upper arm tenderness  


add text here
<br>If any 3 or more of the above criteria, or greater than 1 criteria and a clinical abnormality of the temporal artery, are present in a patient then PMR is probable. Definite PMR is characterised by probable PMR that has a positive response to corticosteroid therapy.<br> <br>The Hunder criteria<ref name=":5" />, which includes:


== Differential Diagnosis ==
<br>• Patient age &gt; 50 years<br>• Bilateral aching and tenderness for &gt; 1 month of neck or torso, shoulders or upper arms, and hips or thighs<br>• ESR &gt; 40 mm/hour<br>• Exclusion of other diagnoses <br> All the above Hunder criteria must be present to have a diagnosis of definite PMR. <br> Both of the above criteria have been found to have a sensitivity of &gt;90%.  


add text here
The European League Against Rheumatism and American College of Rheumatology have developed classification criteria rather then diagnostic criteria, which must still be validated, and can only be applied to patients in whom new-onset bilateral shoulder pain is not attributable to an alternative diagnosis: <ref name=":4" />


== Case Reports/ Case Studies  ==
====The European League Against Rheumatism and American College of Rheumatology provisional criteria for classification of polymyalgia Rheumatica<ref>Dasgupta B et al ,2012 provisional classifi cation criteria for polymyalgia rheumatica: a European League Against Rheumatism/ American College of Rheumatology collaborative initiative, Ann Rheum Dis 2012; 71: 484-92 LOE&nbsp;: 5</ref><ref>Dasgupta B et al ,2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative., Arthritis Rheum, 2012;64:943-54 LOE&nbsp;: 5</ref> ====
<br><u>Clinical criteria for scoring algorithm</u><br> <br>2 points - Morning stiffness lasting more than 45 min &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<br>1 point - Hip pain or restricted range of motion &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp;  &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<br>2 points - Absence of rheumatoid factor and antibody to cyclic citrullinated peptide &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; <br>1 point - Absence of other joint involvement &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<br> <br><u>Ultrasound criteria for scoring algorithm</u><br> <br>1 point - At least 1 shoulder with subdeltoid bursitis, biceps tenosynovitis, or glenohumeral synovitis; 


*Polymyalgia rheumatic and exercise: a single case report on one woman
and at least one hip with synovitis or trochanteric bursitis &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;                                                                           
*Isolated lower extremity vasculitis in a patient with polymyalgia rheumatica


== Resources <br> ==
1 point - Both shoulders with subdeltoid bursitis, biceps tenosynovitis, or glenohumeral synovitis &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp;


*American College of Rheumatology- http://www.rheumatology.org/practice/clinical/patients/diseases_and_conditions/polymyalgiarheumatica.asp
<br><u>Inclusion criteria for use of this classification system:</u>
*National Library of Medicine - http://www.nlm.nih.gov/medlineplus/polymyalgiarheumatica.html
* age 50 years or older
*National Institute of Arthritis and Musculoskeletal and Skin Diseases Information Clearinghouse - http://www.niams.nih.gov/Health_Info/Polymyalgia/default.asp
* bilateral shoulder pain
*Arthritis Foundation - http://www.arthritis.org/conditions/diseasecenter/pmr.asp
* abnormal ESR, C-reactive protein, or both.     With only clinical criteria, a score of greater than 4 had a sensitivity of 68&nbsp;% and a specificity of 78&nbsp;% for discriminating polymyalgia rheumatic form comparison patients.<br>With combination of clinical criteria and ultrasound criteria, a score of greater than 5 had a sensitivity of 66&nbsp;% and specific of 81&nbsp;% for discriminating patients with the disorder from comparison


== Recent Related Research (from [http://www.ncbi.nlm.nih.gov/pubmed/ Pubmed]) ==
== Treatment ==
<br>PMR is generally treated with a long course of corticosteroids. There is no consensus on the initial dosage and subsequent titration of the corticosteroid dosage. Some suggest an initial dose of 15-20 mg/day of prednisone and then a slow tapering over several weeks or months to find a maintenance dosage.Although PMR responds very well to corticosteroids, there is still concern for the adverse effects that occur with long-term steroid use. This includes diabetes, osteoporosis, hypertension, worsening of cataracts, muscle weakness, and infection. Patients taking corticosteroids must have their blood sugar, blood pressure, and body weight routinely checked. Due to the increased risk for osteoporosis, vitamin D and calcium supplements should be initiated when the corticosteroids are initiated.<ref>Nothnagl T, Leeb B. Diagnosis, Differential Diagnosis and Treatment of Polymyalgia Rheumatica. Drugs &amp;Aging [serial online]. May 2006;23(5):391. Available from: Academic Search Premier, Ipswich, MA. Accessed April 5, 2011.</ref>


see tutorial on [[Adding PubMed Feed|Adding PubMed Feed]]
<br>Complete clinical remission may take up to 5 years to occur.<ref>Goodman CC, Fuller KS. Pathology: Implications for the Physical Therapist. 3rd ed. St. Louis: Saunders Elsevier; 2009. (LOE 5)</ref><br><br>&nbsp;
<div class="researchbox">
== Physical Therapy Management&nbsp; ==
<rss>Feed goes here!!|charset=UTF-8|short|max=10</rss>  
</div>  
== References ==


see [[Adding References|adding references tutorial]].  
There is currently no evidence for the use of physical therapy in the treatment of patients with PMR. However, it is still important to be aware that patients may still be referred to you with a primary diagnosis of PMR, or with PMR as a co-morbidity. Physical therapy can be incorporated as a valuable component of a therapeutic regiment for this patient group in order to reduce the risk of early functional impairment and severe disability.<ref>Wollenhaupt et al, Geriatric rheumatology: Special aspects of clinical diagnostics and therapy of rheumatic diseases in the elderly, 2000. (LOE 3B)</ref> A combination of exercise therapy and education is recommended in the treatment of PMR.  


<references />  
== Multidisciplinary Team in management of PMR ==
Research suggests that low-dose glucocorticoids effectively alleviate musculoskeletal symptoms related to PMR. In some countries, PMR management involves a collaborative effort between various experts in rheumatology, occupational therapy, physical therapy, rehabilitation, social work, nursing, manual therapy, podiatry, dietary, psychology, vocational counselling, and orthopedic surgery. However, the effectiveness of this approach in enhancing the health outcomes of PMR patients' needs to be more adequately studied<ref>Uhlig, T., Bjørneboe, O., Krøll, F. ''et al.'' [https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-016-0870-9 Involvement of the multidisciplinary team and outcomes in inpatient rehabilitation among patients with inflammatory rheumatic disease]. ''BMC Musculoskelet Disord'' 17, 18 (2016)</ref>.


[[Category:Bellarmine_Student_Project]]
== References ==
[[Category:Medical]]  
[[Category:Rheumatology]]
[[Category:Global Health]]
[[Category:Primary Contact]]
<references />

Latest revision as of 12:21, 27 September 2023

Definition/Description [edit | edit source]

Polymyalgia rheumatica (PMR) is a rheumatic inflammatory disorder that has an unknown cause.[1] It causes inflammation of the large muscles of the body and can be accompanied by systematic symptoms including malaise, fatigue, fever, and weight loss.[2] In patients with PMR, the synovial membranes and bursae that line and lubricate the joints become inflamed, causing pain and discomfort. Unlike in some other inflammatory diseases, there is no associated permanent damage to the joints or the muscles.[2] Polymyalgia rheumatic is also known as muscular rheumatism.[3] PMR is a heterogeneous disease with a major impact on QOL. [4]

Clinically Relevant Anatomy[edit | edit source]

PMR is a condition that causes many (poly) painful muscles (myalgia)[5]. PMR characteristically presents with pain and stiffness in the shoulder and hip girdles and an elevated acute phase response. [6]

Polymyalgiafoto1.GIF

Epidemiology/etiology[edit | edit source]

Although polymyalgia rheumatic occurs worldwide, the highest incidence is seen in Scandinavian countries and in people of the northern European descent. [16] In the United States the lifetime risk of developing PMR is estimated at 2.43% for women and 1.66% for men. The lowest incidence rates occur at the more southern European countries like Italy, and Spain. [7]

PMR is most commonly diagnosed in persons over the age of 50, PMR has a prevalence of approximately 7 in 100 for people over 50 years of age and 4 in 10,000 in adults over 60 years of age. The prevalence is gender dependent with the ratio of men to women affected 1:2. [3] The disease is more common in Caucasian.
[8]


Some of the characteristics of PMR suggest that infectious disease expose could be an environmental factor. The disease has a very sudden onset and new cases occur in cycles, which could indicate an infection as the source. Attention has been focused on Chlamydia, Mycoplasma, parainfluenza virus or parvovirus B19 as possible infections responsible for developing PMR. Inheritance of the disorder has been suggested due to findings in some genetic studies and the pattern seen in family histories.[9] The gene(s) that could be responsible for PMR have not been definitively identified. The HLA-DRB104 and HLA-DRB01 alleles have both been found to have a possible link to PMR and GCA although this remains controversial.[10]

There may be an imbalance between immunosuppressive T-regulatory (Treg) lymphocytes and proinflammatory T-helper 17 (Th17) cells in PMR and giant cell arteritis (GCA). The frequency of Treg cells circulating appears to be reduced in patients with PMR compared with aged-matched volunteers. While on the other hand TH17 cells appear to be increased. [9]

    

Characteristics/Clinical Presentation[edit | edit source]

Polymyalgiafoto2.GIF

   

The onset of PMR is very sudden. Individuals can usually remember the exact time and day that symptoms began. Individuals often wake up one morning with extreme stiffness and soreness for no apparent reason. Synovitis and bursitis of the shoulder and hip are the cause of the patient's pain and symptoms are typically bilateral[10]

Other symptoms that are found in 40-50% of patients and include:
• stiffness after rising in the morning lasting 30 min or longer or after resting
• weakness
• fatigue
• malaise
• low-grade fever
• sweats
• headache
• weight loss
• depression
• vision changes

The symptom pattern is characteristic to PMR, although, several other autoimmune, infectious, endocrine and malignant disorders can present with similar symptoms. Ruling out the other illnesses is very important.

Differential Diagnosis[edit | edit source]

There are many conditions that can mimic PMR, like rheumatoid arthritis (RA) and spondyloarthropathies (SpA). Pain and swelling of the distal joints, like feet, hands and wrists should raise concern for an inflammatory arthritis. Some patients may present swelling and pitting edema of the hands and the feet, because of a tenosynovitits. The so called remitting seronegative symmetrical synovitis with pitting edema syndrome.[10]

PMR must be differentiated from :

Rheumatological diseases such as:

  • Rheumatoid Arthritis
  • Spondyloarthropathy
  • Crystalline Arthritis (calcium pyrophosphate disease and calcium hydroxyapatite disorders)
  • Remitting seronegative symmetric synovitis with pitting oedema syndrome
  • Connective tissue diseases
  • Vasculitis (giant cell arteritis, antineutrophil cytoplasmic antibody-associated vasculitis).
  • Inflammatory myopathies (dermatomyositis, polymyositis )

Non-inflammatory musculoskeletal disorders such as

  • Rotator-cuff diseases (rotator cuff tears, rotator cuff tendinopathy)
  • Adhesive capsulitis
  • Degenerative joint disease (degeneratieve disc disease)
  • Fibromyalgia
  • Endocrinopathies
  • Thyroid diseases
  • Disorders of the parathyroid gland
  • Infections - viral or bacterial i.e. sepsis, ends carditis, septic arthritis
  • Mycobacterial – eg tuberculosis
  • Malignant diseases
  • Parkinsonism
  • Depression
  • Hypovitaminosis D
  • Drug-induced myopathy-eg, from statins

Diagnostic Procedures[edit | edit source]

Polymyalgia rheumatica is a clinical diagnosis . A careful history and physical examination are crucial in distinguishing this syndrome from other disorders that may present similarly, especially seronegative RA and paraneoplastic syndrome. Laboratory findings are non specific and show characteristic features of systemic inflammation. These include; anaemia, leukocytosis and raised markers of inflammation (ESR and CRP) and sometimes liver tests such as transaminases or alkaline phosphatase are raised. Some clinicians use an erythrocyte sedimentation rate (ESR) of higher than 30 or 40 mm/hr as a diagnostic criterium; however, 6-20% of patients with the disease have a normal sedimentation[11]. Auto-antibodies including rheumatoid factor and antibody to cyclic citrullinated peptide, are usually negative, and if positive, RA must be considered.

Shoulder, hip, neck and upper arm pain associated with PMR is usually bilateral and symmetrical. Tenderness to palpation is expected however muscle weakness is not a feature of PMR. Usually, there will be minimal muscle atrophy unless the disease progression is advanced, when disuse atrophy can occur[12]. Active range of motion is generally reduced due to pain. The 24-hour picture pattern of PMR typically presents with severe morning stiffness that improves somewhat by the evening and following periods of rest. Pain may radiate and mild synovitis may be seen in the wrist and knees. Associated systemic symptoms may include fatigue, fever and weight loss.

Radiographs of the affected joints in PMR are only useful for excluding alternative conditions. In the classification study of the EULAR/ACR, they found a high specificity for ultrasonography for discriminating PMR from other shoulder conditions (89%), but not for discriminating PMR from RA (70%)[13]

Ultrasound (US) may be of value in the diagnosis of PMR. Shoulder abnormalities found using US, such as bursitis and tenosynovitis of the long head of the biceps tendon, is more likely to be seen in patients with PMR. However, in the absence of suggestive clinical features, the presence of isolated US abnormalities should not lead to a diagnosis of PMR.[14]

Diagnostic Criteria[edit | edit source]

There are two sets of diagnostic criteria that have been created for PMR.

The Bird/Wood criteria[15], which includes:


• Bilateral shoulder stiffness
• Duration onset < 2 weeks
• Initial ESR > 40 mm/hour
• Stiffness > 60 minutes
• Age > 65 years
• Depression and/or weight loss
• Bilateral upper arm tenderness


If any 3 or more of the above criteria, or greater than 1 criteria and a clinical abnormality of the temporal artery, are present in a patient then PMR is probable. Definite PMR is characterised by probable PMR that has a positive response to corticosteroid therapy.

The Hunder criteria[15], which includes:


• Patient age > 50 years
• Bilateral aching and tenderness for > 1 month of neck or torso, shoulders or upper arms, and hips or thighs
• ESR > 40 mm/hour
• Exclusion of other diagnoses
All the above Hunder criteria must be present to have a diagnosis of definite PMR.
Both of the above criteria have been found to have a sensitivity of >90%.

The European League Against Rheumatism and American College of Rheumatology have developed classification criteria rather then diagnostic criteria, which must still be validated, and can only be applied to patients in whom new-onset bilateral shoulder pain is not attributable to an alternative diagnosis: [11]

The European League Against Rheumatism and American College of Rheumatology provisional criteria for classification of polymyalgia Rheumatica[16][17][edit | edit source]


Clinical criteria for scoring algorithm

2 points - Morning stiffness lasting more than 45 min                                                                                                                        
1 point - Hip pain or restricted range of motion                                                                                                                              
2 points - Absence of rheumatoid factor and antibody to cyclic citrullinated peptide                                                                    
1 point - Absence of other joint involvement                                                                                                                                      

Ultrasound criteria for scoring algorithm

1 point - At least 1 shoulder with subdeltoid bursitis, biceps tenosynovitis, or glenohumeral synovitis;

and at least one hip with synovitis or trochanteric bursitis                      

1 point - Both shoulders with subdeltoid bursitis, biceps tenosynovitis, or glenohumeral synovitis                                              


Inclusion criteria for use of this classification system:

  • age 50 years or older
  • bilateral shoulder pain
  • abnormal ESR, C-reactive protein, or both. With only clinical criteria, a score of greater than 4 had a sensitivity of 68 % and a specificity of 78 % for discriminating polymyalgia rheumatic form comparison patients.
    With combination of clinical criteria and ultrasound criteria, a score of greater than 5 had a sensitivity of 66 % and specific of 81 % for discriminating patients with the disorder from comparison

Treatment[edit | edit source]


PMR is generally treated with a long course of corticosteroids. There is no consensus on the initial dosage and subsequent titration of the corticosteroid dosage. Some suggest an initial dose of 15-20 mg/day of prednisone and then a slow tapering over several weeks or months to find a maintenance dosage.Although PMR responds very well to corticosteroids, there is still concern for the adverse effects that occur with long-term steroid use. This includes diabetes, osteoporosis, hypertension, worsening of cataracts, muscle weakness, and infection. Patients taking corticosteroids must have their blood sugar, blood pressure, and body weight routinely checked. Due to the increased risk for osteoporosis, vitamin D and calcium supplements should be initiated when the corticosteroids are initiated.[18]


Complete clinical remission may take up to 5 years to occur.[19]

 

Physical Therapy Management [edit | edit source]

There is currently no evidence for the use of physical therapy in the treatment of patients with PMR. However, it is still important to be aware that patients may still be referred to you with a primary diagnosis of PMR, or with PMR as a co-morbidity. Physical therapy can be incorporated as a valuable component of a therapeutic regiment for this patient group in order to reduce the risk of early functional impairment and severe disability.[20] A combination of exercise therapy and education is recommended in the treatment of PMR.

Multidisciplinary Team in management of PMR[edit | edit source]

Research suggests that low-dose glucocorticoids effectively alleviate musculoskeletal symptoms related to PMR. In some countries, PMR management involves a collaborative effort between various experts in rheumatology, occupational therapy, physical therapy, rehabilitation, social work, nursing, manual therapy, podiatry, dietary, psychology, vocational counselling, and orthopedic surgery. However, the effectiveness of this approach in enhancing the health outcomes of PMR patients' needs to be more adequately studied[21].

References[edit | edit source]

  1. Goodman, Snyder. Differential Diagnosis for Physical Therapists: Screening for Referral. St. Louis Missouri. 2007.
  2. 2.0 2.1 LeGrove L. Polymyalgia rheumatica: management guidelines. Practice Nurse [serial online]. May 8, 2009;37(9):33-37. Available from: CINAHL with Full Text, Ipswich, MA. Accessed April 4, 2011.
  3. 3.0 3.1 Reumafonds: polymyalgia rheumatica. http://www.reumalier.be/PDF-FILES/112.juli13_BS_Polymyalgia_Reumatica.pdf. Accessed July 2013. (LOE 5)
  4. Hutchings A et al, Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica., Arthritis Rheum. 2007 Jun 15;57(5):803-9 LOE: 2a
  5. Arthritis New Zealand: http//www.arthritis.org.nz/wp-content/uploads/2012/06/4618_Polymyalgia_Flyer_4-1.pdf
  6. Sara Muller et al., The epidemiology of polymyalgia rheumatica in primary care: a research protocol, BMC Musculoskelet Disord. 2012; 13: 102. LOE: 2a
  7. Advances and challenges in the diagnosis and treatment of polymyalgia rheumatica; Tanaz A. Kermani et al.; February 6 2014. LOE:2a
  8. Siebert S, Lawson T, Wheeler M, Martin J, Williams B. Polymyalgia rheumatica: pitfalls in diagnosis. Journal Of The Royal Society Of Medicine [serial online]. May 2001;94(5):242-244. Available from: MEDLINE, Ipswich, MA. Accessed April 5, 2011.
  9. 9.0 9.1 Mayo Clinic: Polymyalgia rheumatica.http://www.mayoclinic.com/health/polymyalgia-rheumatica/DS00441. Accessed March 31, 2011.
  10. 10.0 10.1 10.2 Nothnagl T, Leeb B. Diagnosis, Differential Diagnosis and Treatment of Polymyalgia Rheumatica. Drugs &Aging [serial online]. May 2006;23(5):391. Available from: Academic Search Premier, Ipswich, MA. Accessed April 5, 2011.
  11. 11.0 11.1 Tanza A Kermani et al, Polymyalgia rheumatic, Lancet 2013 : 381 : 63-72.LOE : 2A
  12. Clement J michet etal . Polymyalgia rheumatic . BMJ 2008;336. (LOE: 2A)
  13. Advances and challenges in the diagnosis and treatment of polymyalgia rheumatica; Tanaz A. Kermani et al.; February 6 2014. LOE:2a
  14. Sakellariou G et al, Ultrasound imaging for the rheumatologist XLIII. Ultrasonographic evaluation of shoulders and hips in patients with polymyalgia rheumatica: a systematic literature review. Clin. Exp. Rheumatol. 2013;31:1-7. LOE : 3A
  15. 15.0 15.1 Nothnagl T, Leeb B. Diagnosis, Differential Diagnosis and Treatment of Polymyalgia Rheumatica. Drugs &Aging [serial online]. May 2006;23(5):391. Available from: Academic Search Premier, Ipswich, MA. Accessed April 5, 2011.
  16. Dasgupta B et al ,2012 provisional classifi cation criteria for polymyalgia rheumatica: a European League Against Rheumatism/ American College of Rheumatology collaborative initiative, Ann Rheum Dis 2012; 71: 484-92 LOE : 5
  17. Dasgupta B et al ,2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative., Arthritis Rheum, 2012;64:943-54 LOE : 5
  18. Nothnagl T, Leeb B. Diagnosis, Differential Diagnosis and Treatment of Polymyalgia Rheumatica. Drugs &Aging [serial online]. May 2006;23(5):391. Available from: Academic Search Premier, Ipswich, MA. Accessed April 5, 2011.
  19. Goodman CC, Fuller KS. Pathology: Implications for the Physical Therapist. 3rd ed. St. Louis: Saunders Elsevier; 2009. (LOE 5)
  20. Wollenhaupt et al, Geriatric rheumatology: Special aspects of clinical diagnostics and therapy of rheumatic diseases in the elderly, 2000. (LOE 3B)
  21. Uhlig, T., Bjørneboe, O., Krøll, F. et al. Involvement of the multidisciplinary team and outcomes in inpatient rehabilitation among patients with inflammatory rheumatic disease. BMC Musculoskelet Disord 17, 18 (2016)